Drug Profile

ALG 020572

Alternative Names: ALG-020572

Latest Information Update: 17 Feb 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aligos Therapeutics
Class Antisense oligonucleotides; Antivirals
Mechanism of Action RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Hepatitis B

Most Recent Events

06 Feb 2023 Aligos Therapeutics completes a phase I trial for Hepatitis B (In volunteers) in United Kingdom and New Zealand (SC) (NCT05001022)
22 Jun 2022 Adverse events and pharmacokinetic data from a phase Ib trial in Hepatitis B presented at The International Liver Congress 2022 (ILC-2022)
03 May 2022 Aligos Therapeutics has patents pending for ALG 020572 in US

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com